Literature DB >> 25170011

Lichenoid mucosal reaction to rituximab.

Michal Kuten-Shorrer1, Ephraim P Hochberg2, Sook-Bin Woo3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25170011      PMCID： PMC4200996          DOI： 10.1634/theoncologist.2014-0169

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  7 in total

Review 1.  Lichen planus, lichenoid drug reactions, and lichenoid mucositis.

Authors:  Scott S DeRossi; Katharine N Ciarrocca
Journal:  Dent Clin North Am       Date:  2005-01

Review 2.  Immunotherapies in rheumatologic disorders.

Authors:  Anne V Miller; Sriya K M Ranatunga
Journal:  Med Clin North Am       Date:  2012-05-01       Impact factor: 5.456

Review 3.  Tolerability and safety of rituximab (MabThera).

Authors:  Eva Kimby
Journal:  Cancer Treat Rev       Date:  2005-07-28       Impact factor: 12.111

Review 4.  Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations.

Authors:  Ibtisam Al-Hashimi; Mark Schifter; Peter B Lockhart; David Wray; Michael Brennan; Cesar A Migliorati; Tony Axéll; Alison J Bruce; William Carpenter; Ellen Eisenberg; Joel B Epstein; Palle Holmstrup; Mats Jontell; Francina Lozada-Nur; Raj Nair; Bud Silverman; Kobkan Thongprasom; Martin Thornhill; Saman Warnakulasuriya; Isaäc van der Waal
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2007-01-29

5.  Initial management strategies for follicular lymphoma.

Authors:  Qiushi Chen; Turgay Ayer; Loretta J Nastoupil; Miray Seward; Hongzheng Zhang; Rajni Sinha; Christopher R Flowers
Journal:  Int J Hematol Oncol       Date:  2012-10

Review 6.  A review of the current use of rituximab in autoimmune diseases.

Authors:  Hakan M Gürcan; Derin B Keskin; Joel N H Stern; Matthew A Nitzberg; Haris Shekhani; A Razzaque Ahmed
Journal:  Int Immunopharmacol       Date:  2008-11-08       Impact factor: 4.932

7.  GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption.

Authors:  Waseem Bakkour; Ian H Coulson
Journal:  Dermatol Ther (Heidelb)       Date:  2012-03-30
  7 in total
  5 in total

1.  Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.

Authors:  Souraya El Sankari; Cyril Van Essche; Vincent van Pesch
Journal:  J Neurol       Date:  2021-06-28       Impact factor: 4.849

Review 2.  Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.

Authors:  Megan H Trager; Donatienne de Clippelé; Caroline Ram-Wolff; Adèle de Masson; Marie-Dominique Vignon-Pennamen; Maxime Battistella; Laurence Michel; Martine Bagot; Gabor Dobos
Journal:  Acta Derm Venereol       Date:  2020-05-28       Impact factor: 3.875

Review 3.  Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.

Authors:  Yoshiaki Yura; Masakazu Hamada
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

Review 4.  Oral lichenoid lesion in association with chemotherapy treatment for non-Hodgkin lymphoma or lichen planus? Review of the literature and report of two challenging cases.

Authors:  Letícia Côgo Marques; Laiza Angela de Medeiros Nunes da Silva; Pâmella de Pinho Montovani Santos; Amanda de Almeida Lima Borba Lopes; Karin Soares Cunha; Adrianna Milagres; Rafaela Elvira Rozza-de-Menezes; Arley Silva Junior; Danielle Castex Conde
Journal:  Head Face Med       Date:  2022-09-06       Impact factor: 2.246

5.  Oral Lichenoid Reaction: An Uncommon Side Effect of Rituximab.

Authors:  Amerigo Giudice; Francesco Liborio; Fiorella Averta; Selene Barone; Leonzio Fortunato
Journal:  Case Rep Dent       Date:  2019-11-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.